Other notable inhibitors such as SRI-37330, DI-NBP, W2476, quercetin, allopurinol, and salidroside have demonstrated promising effects across various disease models, including diabetes, nonalcoholic fatty liver disease, and diabetic nephropathy, targeting different mechanisms of TXNIP action [173]. The gene discussed is TXNIP; the disease is metabolic dysfunction-associated steatotic liver disease.